Short Interest in Onconetix Drops by 76.1%

Hedge fund Pacific Capital Wealth Advisors Inc. purchased a new stake in the biotech company.

Mar. 10, 2026 at 10:22pm

Got story updates? Submit your updates here. ›

Onconetix, Inc. (NASDAQ:ONCO) saw a significant 76.1% drop in short interest in February, with short interest totaling 37,915 shares as of February 27th, down from 158,751 shares on February 12th. The company's average daily trading volume is 143,032 shares, giving it a days-to-cover ratio of 0.3 days. Pacific Capital Wealth Advisors Inc. recently purchased a new position in Onconetix, owning approximately 0.84% of the company's shares.

Why it matters

The sharp decline in short interest suggests increased investor confidence in Onconetix, a biotechnology company focused on men's health and oncology solutions. The new stake by Pacific Capital Wealth Advisors also indicates institutional interest in the company, which could signal positive momentum.

The details

Onconetix, Inc. is a biotechnology company that focuses on the research, development, and commercialization of solutions for men's health and oncology. The company offers Entadfi, an FDA-approved pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia, as well as Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer.

  • As of February 27th, 2026, there was short interest totaling 37,915 shares.
  • On February 12th, 2026, the short interest totaled 158,751 shares.

The players

Onconetix, Inc.

A biotechnology company focused on men's health and oncology solutions, including FDA-approved products for benign prostatic hyperplasia and prostate cancer diagnostics.

Pacific Capital Wealth Advisors Inc.

A hedge fund that recently purchased a new position in Onconetix, owning approximately 0.84% of the company's shares.

Got photos? Submit your photos here. ›

The takeaway

The significant drop in short interest and the new institutional investment in Onconetix suggest growing investor confidence in the company's products and future prospects in the men's health and oncology markets.